Publication Name	World Journal of Clinical Cases
Manuscript ID	80185
Country	United Kingdom

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Emerging role of dual biologic therapy for the treatment of inflammatory bowel disease
Manuscript Source	Invited Manuscript
All Author List	Matthew D McCormack, Natasha A Wahedna, David Aldulaimi and Peter Hawker
Funding Agency and Grant Number
Corresponding Author	Matthew D McCormack, MBChB, Doctor, Department of Gastroenterology, South Warwickshire NHS Foundation Trust, Warwick Hospital, Lakin Road, Warwick CV34 5BW, United Kingdom. m.mccormack3@nhs.net
Key Words	Dual biologic therapy; Inflammatory bowel disease; Crohn’s disease; Ulcerative colitis; Combination therapy; Biologic safety
Core Tip	For patients with difficult to treat or refractory inflammatory bowel disease (IBD), biologic therapy and combination therapy with small molecule agents has helped improve patient outcomes and maintenance success. There is growing interest in the use of dual biologic therapy in IBD but published data remains limited. Whilst initial data suggests positive effects on reduction in morbidity, more studies are still required in this emerging area with further comparison of different biologic combinations and their safety profiles.
Citation	McCormack MD, Wahedna NA, Aldulaimi D, Hawker P. Emerging role of dual biologic therapy for the treatment of inflammatory bowel disease. World J Clin Cases 2023; 11(12): 2621-2630

Received	2022-09-19 19:58
Peer-Review Started	2022-09-19 20:00
To Make the First Decision
Return for Revision	2022-10-24 07:15
Revised	2023-02-07 15:32
Second Decision	2023-03-24 02:57
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2023-03-24 05:58
Articles in Press	2023-03-24 05:58
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2023-04-10 12:19

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com